CORT - Joseph K Belanoff Makes A Tactical Move: Adds Corcept Therapeutics Stock Options To Portfolio | Benzinga
Disclosed in a recent SEC filing, Joseph K Belanoff, Chief Executive Officer at Corcept Therapeutics (NASDAQ:CORT), made a strategic move by acquiring company stock options on February 14,.
What Happened: Revealed in a Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission, Belanoff, Chief Executive Officer at Corcept Therapeutics, strategically acquired stock options for 500,000 shares of CORT. These options empower Belanoff to buy the company's stock at a favorable exercise price of $23.01 per share.
Currently, Corcept Therapeutics shares are trading down 0.0%, priced at $23.05 during Wednesday's morning. This values Belanoff's 500,000 shares at $19,999.
Unveiling the Story Behind Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Corcept Therapeutics: Delving into Financials
Positive Revenue Trend: Examining Corcept Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 21.5% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations ...